Cost-effectiveness of two models of management for patients on chronic warfarin therapy – a Markov model analysis

Summary

Allocation of additional resources for establishing or expanding anticoagulation clinic (AC) services is a significant concern for healthcare decision-makers when the payer is also the provider of the healthcare system. The majority of anticoagulated patients in Hong Kong are managed by routine medical care (RMC) instead of ACs, possibly due to the lack of local cost-effectiveness analysis of the AC setting. The aim was to compare the clinical and economic outcomes of anticoagulated patients who were managed by AC or RMC from the perspective of a public health organization in Hong Kong. A Markov model was designed to simulate, over 10 years, the economic and clinical outcomes of patients receiving chronic warfarin therapy managed by AC or RMC. The transition probabilities were derived from literature. Resource utilization was retrieved from patients managed by AC and RMC in Hong Kong. Sensitivity analysis was conducted to examine the robustness of the model. The total number of events per 100 patient-years and the direct medical cost per patient-year in the AC and RMC groups were 9.5 and USD 840, and, 19.3 and USD 1,179, respectively. The results of the model were sensitive to the variation of the probability of major bleeding in the AC group. In conclusion, the coordinated care provided by an anticoagulation clinic appears to be more cost-effective than routine medical care in the management of warfarin therapy from the perspective of public health organization in Hong Kong.

Keywords

Warfarin - cost-effectiveness - Markov model

• References

• 1 Errichette AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med 1984; 144: 1966-8.
• 2 Petty GW, Lennihan L, Mohr JP. et al. Complications of long-term anticoagulation. Ann Neurol 1988; 23: 570-4.
• 3 Charney R, Leddomado E, Rose DN. et al. Anticoagulation clinics and the monitoring of anticoagulation therapy. Int J Cardiol 1988; 18: 197-206.
• 4 Searbrook GR, Karp D, Schmitt DD. et al. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg 1990; 160: 501-5.
• 5 Cannegieter SC, Rosendaal FR, Wintzen AR. et al. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
• 6 Cortelazzo S, Finazzi G, Viero P. et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-20.
• 7 Wilt VM, Gums JG, Ahmed I O. et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy 1995; 15: 732-9.
• 8 Chiquette E, Amato MG, Bussey I H. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
• 9 Poli D, Antonucci E, Lombardi A. et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003; 14: 269-75.
• 10 Fihn SD, Callahan CM, Martin DC. et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-9.
• 11 Holm T, Lassen JF, Husted SE. et al. A ran-domized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002; 252: 322-31.
• 12 Fihn SD, McDonell M, Martin D. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-20.
• 13 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
• 14 Van der Meer FJM, Rosendaal FR, Vandenbroucke JP. et al. Bleeding complications in oral anticoagulant therapy. Arch Intern Med 1993; 153: 1557-62.
• 15 Lanefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87144-52.
• 16 Gitter MJ, Jaeger TM, Petterson TM. et al. Bleeding and thromboembolism during anti- coagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clinic Proc 1995; 70: 725-33.
• 17 Website: Hospital Authority, Hong Kong www.ha.org.hk
• 18 Sonnenberg FA, Beck RJ. Markov models in Medical Decision Making: a practice guide. Med Decis Making 1993; 13: 322-38.
• 19 Ansell J, Dalen J, Bussey H. et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
• 20 Ludlam CA, Bennett B, Fox KA. et al. Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis 1995; 6: 273-85.
• 21 Yu HCM, Chan TYK, Critchley JAJH. et al. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996; 89 (02) 127-35.
• 22 Chan TY. Drug interactions as a cause of over anticoagulation and bleedings in Chinese patients receiving warfarin. Int J Clin Pharm Ther 1998; 36: 403-5.
• 23 Chan TY. Adverse interactions between war-farin and nonsteroidal anti-inflammatory drugs: mechanisms. Clinical significance, and avoidance. Ann Pharmacother 1995; 29: 1274-83.